MannKind (MNKD)
(Delayed Data from NSDQ)
$4.32 USD
+0.01 (0.23%)
Updated May 10, 2024 04:00 PM ET
After-Market: $4.32 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum D VGM
Brokerage Reports
0 items in cart
MannKind Corporation [MNKD]
Reports for Purchase
Showing records 201 - 220 ( 228 total )
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
We are maintaining our HOLD recommendation and keeping our target price under review.
Provider: GRIFFIN SECURITIES, INC.
Analyst: MARKEY K
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
We see next Afrezza PDUFA between 22 and 26 months away, estimate MNKD needs another
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Lowered our rating to HOLD and put our 12-month target price under review.
Provider: GRIFFIN SECURITIES, INC.
Analyst: MARKEY K
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Afrezza has similar fate to Bydureon: FDA brings up new issues on second CRL, timelines pushed out
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Afrezza has similar fate to Bydureon: FDA brings up new issues on second CRL, timelines pushed out
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Reports 3Q10; with PDUFA two months away, hoping for no surprise requests by the FDA.
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
R&Rs Week in Review: Oncology and Stem Cell Sectors
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Reports 2Q10 results; gets back on partnership mode while waiting for PDUFA #2
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
A rare, on time/earlier-than-expected, surprise: CRL response sent, accepted by FDA, new PDUFA set
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
ADA data still point to a better, faster insulin;we continue to expect Afrezza in the market in
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.